A mean height difference of 13.59 cm after eight years of treatment — measured against untreated natural history cohorts — is not a marginal signal. It is a structural argument that vosoritide‘s benefit compounds with duration, and it reframes the central clinical question in achondroplasia from whether to treat to how early and for how long.
The three long-term extension trials presented at PES 2026 add important texture beyond standing height. Arm span Z-scores improved from baseline across all age groups, and the arm span-to-height ratio held stable over time — meaning skeletal growth remained proportional rather than selectively elongating one dimension. That matters clinically because disproportionate limb-to-trunk ratios drive many of the orthopedic and respiratory complications that define morbidity in achondroplasia. Separately, a 119-child DXA cohort followed for up to six years showed bone mineral content rising while BMD Z-scores stayed consistent year over year — ruling out the concern that accelerated linear growth might come at the cost of bone integrity. These are not surrogate endpoints chosen for convenience; they map directly onto the complications that prompt surgical intervention.
The hypochondroplasia data are earlier-stage but structurally significant. A Children’s National Hospital Phase 2 study showed a statistically significant improvement in total body minus head BMD of 0.03 g/cm² and BMC of 54.84 g after just 12 months — mirroring the bone-health signal seen in achondroplasia and providing biological plausibility for the ongoing CANOPY-HCH-3 registration trial. Hypochondroplasia is a harder diagnostic target than achondroplasia, often identified later and with more phenotypic variability, which makes enrollment and endpoint consistency in a pivotal trial genuinely challenging. Topline Phase 3 data are expected before mid-2026, with a regulatory submission planned for the second half of the year if results are positive.
The single number to track when CANOPY-HCH-3 reads out is annualized height velocity difference versus placebo at 52 weeks — the same primary endpoint structure that anchored vosoritide’s achondroplasia approval. If that delta clears a clinically meaningful threshold in a condition where the growth impairment is subtler, it validates the CNP analog mechanism across a broader FGFR3-driven dysplasia spectrum and directly determines whether a second approved indication is viable in 2027.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
